Andreas Josefsson
Overview
Explore the profile of Andreas Josefsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
632
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharifi M, Feng E, Rydzewski N, Taylor A, Sperger J, Shi Y, et al.
Mol Oncol
. 2025 Feb;
PMID: 39985777
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease. Several studies have identified transcriptional subtypes of mCRPC, but comprehensive analysis of prognostic gene expression pathways has been limited. Therefore, we...
2.
Ahlin R, Josefsson A, Nybacka S, Landberg R, Stranne J, Steineck G, et al.
Nutr Cancer
. 2024 Sep;
77(1):124-138.
PMID: 39340410
A phytoestrogen-rich diet has been suggested to reduce tumor proliferation among men with prostate cancer, and the effect may differ between men with different polymorphisms of the estrogen receptor-beta gene...
3.
Sharifi M, Shi Y, Chrostek M, Callahan S, Shang T, Berg T, et al.
JCI Insight
. 2024 Sep;
9(18).
PMID: 39315546
Therapies against cell-surface targets (CSTs) represent an emerging treatment class in solid malignancies. However, high-throughput investigations of CST expression across cancer types have been reliant on data sets of mostly...
4.
Cheng T, Noor U, Watts E, Pollak M, Wang Y, McKay J, et al.
BMC Cancer
. 2024 Jun;
24(1):676.
PMID: 38831273
Background: Circulating total insulin-like growth factor-I (IGF-I) is an established risk factor for prostate cancer. However, only a small proportion of circulating IGF-I is free or readily dissociable from IGF-binding...
5.
Josefsson A, Mansson M, Kohestani K, Spyratou V, Wallstrom J, Hellstrom M, et al.
Eur Urol
. 2024 May;
86(3):223-229.
PMID: 38772787
Background And Objective: We investigated whether adding 4Kscore as a reflex test to prostate-specific antigen (PSA) could improve the screening algorithm for prostate cancer (PC). Methods: In the GÖTEBORG-2 PC...
6.
Wikstrom P, Bergh A, Josefsson A, Thysell E, Welen K
Lakartidningen
. 2024 Apr;
121.
PMID: 38656744
Increased molecular knowledge makes it possible to consider not only genetic defects but also expression profiles for precision medicine in advanced prostate cancer. Several prognostic and treatment-predictive classifiers for prostate...
7.
Magnusson C, Augustsson P, Undvall Anand E, Lenshof A, Josefsson A, Welen K, et al.
Anal Chem
. 2024 Apr;
96(18):6914-6921.
PMID: 38655666
Background: There are important unmet clinical needs to develop cell enrichment technologies to enable unbiased label-free isolation of both single cell and clusters of circulating tumor cells (CTCs) manifesting heterogeneous...
8.
Rajwa P, Borkowetz A, Abbott T, Alberti A, Bjartell A, Brash J, et al.
Eur Urol Open Sci
. 2024 Apr;
63:81-88.
PMID: 38572301
Combination therapies in metastatic hormone-sensitive prostate cancer (mHSPC), which include the addition of an androgen receptor signaling inhibitor and/or docetaxel to androgen deprivation therapy, have been a game changer in...
9.
Magnusson C, Augustsson P, Undvall Anand E, Lenshof A, Josefsson A, Welen K, et al.
medRxiv
. 2023 Dec;
PMID: 38106097
Background: There are important unmet clinical needs to develop cell enrichment technologies to enable unbiased label-free isolation of both single cell and clusters of circulating tumor cells (CTCs) manifesting heterogeneous...
10.
Spyratou V, Freyhult E, Bergh A, Thellenberg-Karlsson C, Wikstrom P, Welen K, et al.
Acta Oncol
. 2023 Sep;
62(12):1698-1706.
PMID: 37713321
Background: For metastatic hormone naïve prostate cancer patients, androgen deprivation therapy (ADT) with escalation therapy including docetaxel and/or androgen targeting drugs is the standard therapy. However, de-escalation is preferable to...